• By Deanna Kamienski, Beth Allan, Amanda Micklus, Steven Muntner, and Maureen Riordan
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced August through September 2015.
Ativa Medical closes $23mm Series B round to support micro lab development
Diagnostics firm Ativa Medical Corp. raised $23mm through its Series B round, which included $15mm in new equity and the conversion of $8mm in debt into Series B shares
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.
Restructuring Edition: Unity unveiled more Phase IIb data for lead asset UBX1325 along with plans to shed its workforce while seeking a partner for it and other drugs. Also, Ono is consolidating US employees at one site, Entrada is cutting its workforce by 20% and other recent strategic shifts.
Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.
